Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections
-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform-San Diego, California, Aug 14, 2019 –Forge Therapeutics, Inc. (Forge), a biotechnology company developing [...]